The health sector is on the cusp of a step change that will see patients benefit from treatment that is more focused on the individual than ever before, writes DR WOLFGANG MERTZ, CTO EMEA for Healthcare, Life Sciences and HPC, Dell EMC Isilon.
Through the better use of data and advances in analytics, precision healthcare promises a more personalised approach that will significantly improve the outcome of even the most serious illnesses.
As well as improving patient care, this new level of personalisation also has the potential to meet the increasing cost challenges faced by the healthcare sector by ensuring resources are allocated in the best way.
It’s generating significant traction as a result, with Global Market Insights recently forecasting that the market size will reach $88 billion by 2023.
Not all patients are the same
The fundamental idea behind precision medicine is that one size doesn’t fit all. While some patients respond to a certain treatment, there will be others that don’t.
For example, for one specific type of cancer, just 20 percent of patients respond well to chemotherapy. This means that treating the other 80 percent in the same way is both time consuming and expensive, with little chance of a positive outcome.
As well as environmental and lifestyle factors, these variations in how patients respond to treatment are often down to genetics. While specific patient details and heath history can inform precision medicine, the ability to analyse individual genomes can take it to a new level.
The role of the genome
Analysis of a patient’s genome can identify biomarkers that provide a strong indication of how they will respond to a certain treatment. In short, this means patients can be offered treatment that is most likely to treat their illness successfully.
Genome sequencing reveals the unique code that defines the physical characteristics of a person, including the likelihood that they will develop certain illnesses.
Specialist companies provide genome sequencing but the fact that the human genome was first sequenced just ten years ago and contains more than three billion base pairs, puts the data challenge in perspective.
Many countries have national collections of genomics data, such as Genomics England, which is funded by the NHS. Using this data, patterns can emerge across populations that can be used to inform treatment.
However, there remain a number of challenges before precision medicine can become a practical reality for the average patient.
Getting the infrastructure right
Firstly, health organisations must gain an understanding of where different data is located and how it can be accessed in an appropriate way.
Patient data is often siloed in hospitals (in Electronic Medical Records or PACS, for example) while other useful genomics data could be spread across regions, countries and beyond. The first challenge is therefore to locate and access relevant data. This requires national and international coordination to establish channels and systems that healthcare organisations can use to access the data they need.
Of course, all of this data must then be consolidated in a way that gives it practical value. Data lake technology – for example, Dell EMC’s healthcare data lake – is particularly useful in this respect, as it brings together structured and unstructured data from a wide range of sources in a single location. Once in place, this data can be easily interrogated by analytics tools to generate useful insight.
There will also be challenges around the approach different regions take with their genomics data. Some countries may have a small number of healthcare regions in a simple structure, while others are more complex. Healthcare organisations, government and research institutions will need to work out the best way to work with the relevant stakeholders, including who will lead the data consolidation and how this can be done as efficiently as possible.
In this scenario, it’s likely that the volume of data that organisations have access to will grow over time, as new connections are made and further bodies of research are created. The size of the data lake is therefore likely to grow, so scale-out storage, such as that provided by Dell EMC Isilon, will be another important element of the technology infrastructure needed to support the development of precision medicine.
Making genomics data useable
The latest storage technology will clearly be crucial but there also needs to be a way for GPs and other clinicians to make use of the data when dealing with individual patient cases. The data needs to be presented in a way that can be understood by people who aren’t trained in data science.
The development of platform applications is critical if this progress in data analysis is to make a real impact. Specialist ISVs are already developing applications to deliver these kinds of insights but it will take time for them to be adopted widely.
Security is another key consideration when working with patient data. Strict access controls should therefore be applied and data anonymised where relevant.
As the exciting world of genomics is poised to revolutionise patient care, it’s important that organisations delivering healthcare prepare their technology infrastructure.
Data lakes, scale-out storage and platform applications will all be key technologies in making precision medicine a reality in the coming years. If healthcare organisations put these capabilities in place, they will be able to bring patient care to a whole new level.
Veeam passes $1bn, prepares for cloud’s ‘Act II’
Leader in cloud-data management reveals how it will harness the next growth phase of the data revolution, writes ARTHUR GOLDSTUCK
Veeam Software, the quiet leader in backup solutions for cloud data management,has announced that it has passed $1-billion in revenues, and is preparing for the next phase of sustained growth in the sector.
Now, it is unveiling what it calls Act II, following five years of rapid growth through modernisation of the data centre. At the VeeamON 2019conferencein Miami this week, company co-founder Ratmir Timashev declared that the opportunities in this new era, focused on managing data for the hybrid cloud, would drive the next phase of growth.
“Veeam created the VMware backup market and has dominated it as the leader for the last decade,” said Timashev, who is also executive vice president for sales and marketing at the organisation. “This was Veeam’s Act I and I am delighted that we have surpassed the $1 billion mark; in 2013 I predicted we’d achieve this in less than six years.
“However, the market is now changing. Backup is still critical, but customers are now building hybrid clouds with AWS, Azure, IBM and Google, and they need more than just backup. To succeed in this changing environment, Veeam has had to adapt. Veeam, with its 60,000-plus channel and service provider partners and the broadest ecosystem of technology partners, including Cisco, HPE, NetApp, Nutanix and Pure Storage, is best positioned to dominate the new cloud data management in our Act II.”
In South Africa, Veeam expects similar growth. Speaking at the Cisco Connect conference in Sun City this week, country manager Kate Mollett told Gadget’s BRYAN TURNER that the company was doing exceptionally well in this market.
“In financial year 2018, we saw double-digit growth, which was really very encouraging if you consider the state of the economy, and not so much customer sentiment, but customers have been more cautious with how they spend their money. We’ve seen a fluctuation in the currency, so we see customers pausing with big decisions and hoping for a recovery in the Rand-Dollar. But despite all of the negatives, we have double digit growth which is really good. We continue to grow our team and hire.
“From a Veeam perspective, last year we were responsible for Veeam Africa South, which consisted of South Africa, SADC countries, and the Indian Ocean Islands. We’ve now been given the responsibility for the whole of Africa. This is really fantastic because we are now able to drive a single strategy for Africa from South Africa.”
Veeam has been the leading provider of backup, recovery and replication solutions for more than a decade, and is growing rapidly at a time when other players in the backup market are struggling to innovate on demand.
“Backup is not sexy and they made a pretty successful company out of something that others seem to be screwing up,” said Roy Illsley, Distinguished Analyst at Ovum, speaking in Miami after the VeeamOn conference. “Others have not invested much in new products and they don’t solve key challenges that most organisations want solved. Theyre resting on their laurels and are stuck in the physical world of backup instead of embracing the cloud.”
Illsley readily buys into the Veeam tagline. “It just works”.
“They are very good at marketing but are also a good engineering comany that does produce the goods. Their big strength, that it just works, is a reliable feature they have built into their product portfolio.”
Veeam said in statement from the event that, while it had initially focused on server virtualisation for VMware environments, in recent years it had expanded this core offering. It was now delivering integration with multiple hypervisors, physical servers and endpoints, along with public and software-as-a-service workloads, while partnering with leading cloud, storage, server, hyperconverged (HCI) and application vendors.
This week, it announced a new “with Veeam”program, which brings in enterprise storage and hyperconverged (HCI) vendors to provide customers with comprehensive secondary storage solutions that combine Veeam software with industry-leading infrastructure systems. Companies like ExaGrid and Nutanix have already announced partnerships.
Timashev said: “From day one, we have focused on partnerships to deliver customer value. Working with our storage and cloud partners, we are delivering choice, flexibility and value to customers of all sizes.”
‘Energy scavenging’ funded
As the drive towards a 5G future gathers momentum, the University of Surrey’s research into technology that could power countless internet enabled devices – including those needed for autonomous cars – has won over £1M from the Engineering and Physical Sciences Research Council (EPSRC) and industry partners.
Surrey’s Advanced Technology Institute (ATI) has been working on triboelectric nanogenerators (TENG), an energy harvesting technology capable of ‘scavenging’ energy from movements such as human motion, machine vibration, wind and vehicle movements to power small electronic components.
TENG energy harvesting is based on a combination of electrostatic charging and electrostatic induction, providing high output, peak efficiency and low-cost solutions for small scale electronic devices. It’s thought such devices will be vital for the smart sensors needed to enable driverless cars to work safely, wearable electronics, health sensors in ‘smart hospitals’ and robotics in ‘smart factories.’
The ATI will be partnered on this development project with the Georgia Institute of Technology, QinetiQ, MAS Holdings, National Physical Laboratory, Soochow University and Jaguar Land Rover.
Professor Ravi Silva, Director of the ATI and the principal investigator of the TENG project, said: “TENG technology is ideal to power the next generation of electronic devices due to its small footprint and capacity to integrate into systems we use every day. Here at the ATI, we are constantly looking to develop such advanced technologies leading towards our quest to realise worldwide “free energy”.
“TENGs are an ideal candidate to power the autonomous electronic systems for Internet of Things applications and wearable electronic devices. We believe this research grant will allow us to further the design of optimized energy harvesters.”